|
US3720760A
(en)
|
1968-09-06 |
1973-03-13 |
Pharmacia Ab |
Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
DE3378250D1
(en)
|
1982-04-22 |
1988-11-24 |
Ici Plc |
Continuous release formulations
|
|
NZ207394A
(en)
|
1983-03-08 |
1987-03-06 |
Commw Serum Lab Commission |
Detecting or determining sequence of amino acids
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
US5128326A
(en)
|
1984-12-06 |
1992-07-07 |
Biomatrix, Inc. |
Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
|
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
ATE243754T1
(de)
|
1987-05-21 |
2003-07-15 |
Micromet Ag |
Multifunktionelle proteine mit vorbestimmter zielsetzung
|
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
|
US5336603A
(en)
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
KR900005995A
(ko)
|
1988-10-31 |
1990-05-07 |
우메모또 요시마사 |
변형 인터류킨-2 및 그의 제조방법
|
|
EP0394827A1
(en)
|
1989-04-26 |
1990-10-31 |
F. Hoffmann-La Roche Ag |
Chimaeric CD4-immunoglobulin polypeptides
|
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
|
WO1991005548A1
(en)
|
1989-10-10 |
1991-05-02 |
Pitman-Moore, Inc. |
Sustained release composition for macromolecular proteins
|
|
WO1991006570A1
(en)
|
1989-10-25 |
1991-05-16 |
The University Of Melbourne |
HYBRID Fc RECEPTOR MOLECULES
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
CA2071867A1
(en)
|
1989-11-06 |
1991-05-07 |
Edith Mathiowitz |
Method for producing protein microspheres
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
|
DK0564531T3
(da)
|
1990-12-03 |
1998-09-28 |
Genentech Inc |
Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
|
|
JP3242916B2
(ja)
|
1990-12-14 |
2001-12-25 |
セル ジェネシス，インコーポレイティド |
レセプター関連シグナル変換系のためのキメラ鎖
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
CA2103059C
(en)
|
1991-06-14 |
2005-03-22 |
Paul J. Carter |
Method for making humanized antibodies
|
|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
|
EP0605522B1
(en)
|
1991-09-23 |
1999-06-23 |
Medical Research Council |
Methods for the production of humanized antibodies
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
|
NL9101953A
(nl)
|
1991-11-21 |
1993-06-16 |
Seed Capital Investments |
Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
|
|
CA2122732C
(en)
|
1991-11-25 |
2008-04-08 |
Marc D. Whitlow |
Multivalent antigen-binding proteins
|
|
WO1993011794A1
(en)
|
1991-12-13 |
1993-06-24 |
Xoma Corporation |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
|
US5869619A
(en)
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
WO1993016185A2
(en)
|
1992-02-06 |
1993-08-19 |
Creative Biomolecules, Inc. |
Biosynthetic binding protein for cancer marker
|
|
US5912015A
(en)
|
1992-03-12 |
1999-06-15 |
Alkermes Controlled Therapeutics, Inc. |
Modulated release from biocompatible polymers
|
|
US5447851B1
(en)
|
1992-04-02 |
1999-07-06 |
Univ Texas System Board Of |
Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
|
|
CA2150262C
(en)
|
1992-12-04 |
2008-07-08 |
Kaspar-Philipp Holliger |
Multivalent and multispecific binding proteins, their manufacture and use
|
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
|
US5834252A
(en)
|
1995-04-18 |
1998-11-10 |
Glaxo Group Limited |
End-complementary polymerase reaction
|
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
|
GB9415379D0
(en)
|
1994-07-29 |
1994-09-21 |
Smithkline Beecham Plc |
Novel compounds
|
|
CN1117155C
(zh)
|
1994-07-29 |
2003-08-06 |
史密丝克莱恩比彻姆有限公司 |
新型化合物
|
|
WO1996020698A2
(en)
|
1995-01-05 |
1996-07-11 |
The Board Of Regents Acting For And On Behalf Of The University Of Michigan |
Surface-modified nanoparticles and method of making and using same
|
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
EP1658772A3
(en)
|
1995-01-17 |
2007-01-17 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US5916597A
(en)
|
1995-08-31 |
1999-06-29 |
Alkermes Controlled Therapeutics, Inc. |
Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
|
|
US5723125A
(en)
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
|
WO1997033899A1
(en)
|
1996-03-14 |
1997-09-18 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule i
|
|
AU728657B2
(en)
|
1996-03-18 |
2001-01-18 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
KR100497017B1
(ko)
|
1996-03-22 |
2005-11-29 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
고사유도분자ii
|
|
WO2002008284A2
(en)
|
2000-07-20 |
2002-01-31 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
|
DE69737418T2
(de)
|
1996-12-26 |
2007-11-29 |
Kyowa Hakko Kogyo Co., Ltd. |
Protein mit der eigenschaft das altern zu unterdrücken
|
|
GB9701425D0
(en)
|
1997-01-24 |
1997-03-12 |
Bioinvent Int Ab |
A method for in vitro molecular evolution of protein function
|
|
US20060246540A1
(en)
|
1997-08-26 |
2006-11-02 |
Ashkenazi Avi J |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US20020042367A1
(en)
|
1997-11-25 |
2002-04-11 |
Genentech, Inc. |
Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
|
|
US20020012961A1
(en)
|
1999-04-15 |
2002-01-31 |
Genentech, Inc. |
Fibroblast growth factor- 19
|
|
US6806352B2
(en)
|
1997-09-17 |
2004-10-19 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
KR100502596B1
(ko)
|
1997-09-17 |
2005-07-22 |
제넨테크, 인크. |
분비 폴리펩티드와 막횡단 폴리펩티드 및 이들을 코딩하는핵산
|
|
US20030113718A1
(en)
|
1997-09-17 |
2003-06-19 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US20030044839A1
(en)
|
1997-09-17 |
2003-03-06 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US5989463A
(en)
|
1997-09-24 |
1999-11-23 |
Alkermes Controlled Therapeutics, Inc. |
Methods for fabricating polymer-based controlled release devices
|
|
SE512663C2
(sv)
|
1997-10-23 |
2000-04-17 |
Biogram Ab |
Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
|
|
WO1999023105A1
(en)
|
1997-11-03 |
1999-05-14 |
Human Genome Sciences, Inc. |
Vegi, an inhibitor of angiogenesis and tumor growth
|
|
US20040126852A1
(en)
|
1997-11-25 |
2004-07-01 |
Genentech, Inc. |
Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
|
|
US20050026832A1
(en)
|
1997-11-25 |
2005-02-03 |
Genentech, Inc. |
Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
|
|
US20020155543A1
(en)
|
1997-11-25 |
2002-10-24 |
Genentech, Inc. |
Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
|
|
WO1999051642A1
(en)
|
1998-04-02 |
1999-10-14 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
BR0008758A
(pt)
|
1999-01-15 |
2001-12-04 |
Genentech Inc |
Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
AU3924300A
(en)
|
1999-04-02 |
2000-10-23 |
Millennium Pharmaceuticals, Inc. |
Fibroblast growth factor-20
|
|
US7390879B2
(en)
|
1999-06-15 |
2008-06-24 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US7129072B1
(en)
|
1999-08-30 |
2006-10-31 |
New York University |
Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
|
|
JP2001072607A
(ja)
|
1999-09-03 |
2001-03-21 |
Kyowa Hakko Kogyo Co Ltd |
新規血管内皮機能改善法
|
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
|
WO2001018209A1
(en)
|
1999-09-10 |
2001-03-15 |
Curagen Corporation |
Fibroblast growth factor polypeptide and nucleic acids encoding same
|
|
US6797695B1
(en)
|
1999-10-22 |
2004-09-28 |
Kyoto University |
Human FGF-20 gene and gene expression products
|
|
PT1232264E
(pt)
|
1999-11-18 |
2009-11-26 |
Novartis Vaccines & Diagnostic |
Gene fgf-21 humano e produtos da expressão do gene
|
|
US6716626B1
(en)
|
1999-11-18 |
2004-04-06 |
Chiron Corporation |
Human FGF-21 nucleic acids
|
|
JP4651893B2
(ja)
|
1999-11-19 |
2011-03-16 |
社団法人芝蘭会 |
新規ポリペプチド、新規ｄｎａ、新規抗体および新規遺伝子改変動物
|
|
DE10160151A1
(de)
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
|
WO2001049849A1
(en)
|
2000-01-05 |
2001-07-12 |
Zymogenetics, Inc. |
Novel fgf homolog zfgf11
|
|
US20010044525A1
(en)
|
2000-01-05 |
2001-11-22 |
Conklin Darrell C. |
Novel FGF Homolog zFGF12
|
|
AU2759201A
(en)
|
2000-01-05 |
2001-07-16 |
Zymogenetics Inc. |
Novel fgf homolog zfgf12
|
|
US20020081663A1
(en)
|
2000-01-05 |
2002-06-27 |
Conklin Darrell C. |
Novel FGF homolog ZFGF11
|
|
US20060160181A1
(en)
|
2000-02-15 |
2006-07-20 |
Amgen Inc. |
Fibroblast Growth Factor-23 molecules and uses thereof
|
|
CA2398603A1
(en)
|
2000-02-15 |
2001-08-23 |
Amgen, Inc. |
Fibroblast growth factor-23 molecules and uses thereof
|
|
US20030211576A1
(en)
|
2000-02-22 |
2003-11-13 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
WO2001066596A2
(en)
|
2000-03-08 |
2001-09-13 |
Chiron Corporation |
Human fgf-23 gene and gene expression products
|
|
WO2001066595A2
(en)
|
2000-03-08 |
2001-09-13 |
Chiron Corporation |
Human fgf-23 gene and gene expression products
|
|
US20020001825A1
(en)
|
2000-03-31 |
2002-01-03 |
Nobuyuki Itoh |
Fibroblast growth factor-like molecules and uses thereof
|
|
US20030065140A1
(en)
|
2000-04-03 |
2003-04-03 |
Vernet Corine A.M. |
Novel proteins and nucleic acids encoding same
|
|
JP2002112772A
(ja)
|
2000-07-10 |
2002-04-16 |
Takeda Chem Ind Ltd |
新規ポリペプチドおよびそのｄｎａ
|
|
CN1446227B
(zh)
|
2000-07-19 |
2011-10-05 |
先端研究与技术学院 |
新型成纤维细胞生长因子(fgf23)及其使用方法
|
|
US6812339B1
(en)
|
2000-09-08 |
2004-11-02 |
Applera Corporation |
Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
|
|
US20070037165A1
(en)
|
2000-09-08 |
2007-02-15 |
Applera Corporation |
Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
|
|
US7265210B2
(en)
|
2000-09-15 |
2007-09-04 |
Genentech, Inc. |
Anti-PRO9821 antibodies
|
|
EP1197755A1
(en)
|
2000-10-11 |
2002-04-17 |
Pepscan Systems B.V. |
Identification of protein binding sites
|
|
US7537902B2
(en)
|
2000-10-24 |
2009-05-26 |
Emory University |
Methods and kits using a molecular interaction between a Smurf-1 WW domain and LIM mineralization protein isoforms
|
|
IL139380A0
(en)
|
2000-10-31 |
2001-11-25 |
Prochon Biotech Ltd |
Active variants of fibroblast growth factor
|
|
WO2002041911A2
(en)
|
2000-11-22 |
2002-05-30 |
Bayer Corporation |
Use of fgf-19 for inhibiting angiogenesis
|
|
US20020151496A1
(en)
|
2000-12-08 |
2002-10-17 |
Bringmann Peter W. |
Novel fibroblast growth factors
|
|
DE10100587C1
(de)
|
2001-01-09 |
2002-11-21 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Zielgens
|
|
DE10100588A1
(de)
|
2001-01-09 |
2002-07-18 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Zielgens
|
|
US7250495B2
(en)
|
2001-06-20 |
2007-07-31 |
Genentech, Inc. |
PRO20044 polypeptides
|
|
AU2002330162B2
(en)
|
2001-10-01 |
2008-08-07 |
Takeda Pharmaceutical Company Limited |
Multi-chain eukaryotic display vectors and uses thereof
|
|
WO2003035842A2
(en)
|
2001-10-24 |
2003-05-01 |
Dyax Corporation |
Hybridization control of sequence variation
|
|
WO2003080803A2
(en)
|
2002-03-21 |
2003-10-02 |
Smithkline Beecham Corporation |
Methods of using farnesoid x receptor (fxr) agonists
|
|
US6987121B2
(en)
|
2002-04-25 |
2006-01-17 |
Smithkline Beecham Corporation |
Compositions and methods for hepatoprotection and treatment of cholestasis
|
|
JP2003334088A
(ja)
|
2002-05-22 |
2003-11-25 |
Pharma Design Inc |
ヒト由来の新規Ｋｌｏｔｈｏ様タンパク質及びその遺伝子
|
|
NZ556507A
(en)
|
2002-06-03 |
2010-03-26 |
Genentech Inc |
Synthetic antibody phage libraries
|
|
MXPA04012243A
(es)
|
2002-06-07 |
2005-02-25 |
Genentech Inc |
Composiciones y metodos para l diagnostico y tratamiento de tumores.
|
|
EP1545584A4
(en)
|
2002-09-18 |
2007-04-04 |
Lilly Co Eli |
METHOD FOR REDUCING MORBIDITY AND MORTALITY OF CRITICAL SICK PATIENTS
|
|
WO2004063355A2
(en)
|
2003-01-10 |
2004-07-29 |
Protein Design Labs, Inc. |
Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
|
|
JP2006240990A
(ja)
*
|
2003-05-15 |
2006-09-14 |
Kirin Brewery Co Ltd |
ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途
|
|
DK1641483T3
(da)
|
2003-06-12 |
2008-06-02 |
Lilly Co Eli |
Fusionsproteiner
|
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
EP1702067A1
(en)
|
2003-12-10 |
2006-09-20 |
Eli Lilly And Company |
Muteins of fibroblast growth factor 21
|
|
PL1751184T3
(pl)
|
2004-05-13 |
2010-02-26 |
Lilly Co Eli |
Białka fuzyjne FGF-21
|
|
JP2006016323A
(ja)
|
2004-06-30 |
2006-01-19 |
Hiroshima Industrial Promotion Organization |
生理活性バイオマテリアル
|
|
US7622445B2
(en)
|
2004-09-02 |
2009-11-24 |
Eli Lilly And Company |
Muteins of fibroblast growth factor 21
|
|
EP2161281A1
(en)
|
2004-09-02 |
2010-03-10 |
Eli Lilly & Company |
Muteins of fibroblast growth factor 21
|
|
AU2005301152A1
(en)
|
2004-10-29 |
2006-05-11 |
Genentech, Inc. |
Disruptions of genes encoding secreted proteins, compositions and methods relating thereto
|
|
WO2006048291A2
(en)
|
2004-11-03 |
2006-05-11 |
Almac Diagnostics Limited |
Transcriptome microarray technology and methods of using the same
|
|
JP2006158339A
(ja)
|
2004-12-09 |
2006-06-22 |
Kyoto Univ |
βＫｌｏｔｈｏ遺伝子、Ｃｙｐ７ａ１遺伝子、及びそれらの利用
|
|
US7655627B2
(en)
|
2004-12-14 |
2010-02-02 |
Eli Lilly And Company |
Muteins of fibroblast growth factor 21
|
|
US20060275794A1
(en)
|
2005-03-07 |
2006-12-07 |
Invitrogen Corporation |
Collections of matched biological reagents and methods for identifying matched reagents
|
|
US7678890B2
(en)
|
2005-07-22 |
2010-03-16 |
Five Prime Therapeutics, Inc. |
Compositions and methods of treating disease with FGFR fusion proteins
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
WO2007025085A2
(en)
|
2005-08-24 |
2007-03-01 |
Genizon Biosciences Inc. |
Genemap of the human genes associated with crohn's disease
|
|
EP1987055A1
(en)
|
2006-02-10 |
2008-11-05 |
Dermagen AB |
Novel antimicrobial peptides and use thereof
|
|
WO2008021196A2
(en)
|
2006-08-09 |
2008-02-21 |
The Mclean Hospital Corporation |
Methods and compositions for the treatment of medical disorders
|
|
CN101563597A
(zh)
|
2006-09-01 |
2009-10-21 |
美国菌种保藏中心 |
用于诊断和治疗2型糖尿病的组合物和方法
|
|
US8394927B2
(en)
|
2006-11-03 |
2013-03-12 |
U3 Pharma Gmbh |
FGFR4 antibodies
|
|
EP2115125B1
(en)
|
2007-01-03 |
2016-09-07 |
NeoStem Oncology, LLC |
Stem cell growth media and methods of making and using same
|
|
ATE554785T1
(de)
|
2007-03-30 |
2012-05-15 |
Ambrx Inc |
Modifizierte fgf-21 polypeptide und ihre verwendung
|
|
NZ580180A
(en)
|
2007-04-02 |
2012-03-30 |
Genentech Inc |
Klotho-beta
|
|
JP5187837B2
(ja)
|
2007-04-06 |
2013-04-24 |
独立行政法人産業技術総合研究所 |
補助因子による受容体の活性化方法並びにリガンド活性の利用方法
|
|
US7537903B2
(en)
*
|
2007-04-23 |
2009-05-26 |
Board Of Regents, The University Of Texas System |
FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
|
|
US10555963B2
(en)
|
2007-05-08 |
2020-02-11 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Klotho protein and related compounds for the treatment and diagnosis of cancer
|
|
WO2008135993A1
(en)
|
2007-05-08 |
2008-11-13 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Klotho protein and related compounds for the treatment and diagnosis of cancer
|
|
EP2036539A1
(en)
|
2007-09-11 |
2009-03-18 |
Novo Nordisk A/S |
Stable formulations of amylin and its analogues
|
|
WO2009076478A2
(en)
|
2007-12-10 |
2009-06-18 |
The Johns Hopkins University |
Hypomethylated genes in cancer
|
|
EP2080812A1
(en)
|
2008-01-18 |
2009-07-22 |
Transmedi SA |
Compositions and methods of detecting post-stop peptides
|
|
US8420088B2
(en)
|
2008-01-28 |
2013-04-16 |
Novartis Ag |
Methods and compositions using FGF23 fusion polypeptides
|
|
TW200936156A
(en)
|
2008-01-28 |
2009-09-01 |
Novartis Ag |
Methods and compositions using Klotho-FGF fusion polypeptides
|
|
US20090226459A1
(en)
|
2008-01-29 |
2009-09-10 |
Cold Spring Harbor Laboratory |
Role of fgf-19 in cancer diagnosis and treatment
|
|
WO2009117622A2
(en)
|
2008-03-19 |
2009-09-24 |
Ambrx, Inc. |
Modified fgf-23 polypeptides and their uses
|
|
NZ579566A
(en)
|
2008-03-19 |
2013-01-25 |
Ambrx Inc |
Modified fgf-21 polypeptides and their uses
|
|
WO2009116861A2
(en)
|
2008-03-21 |
2009-09-24 |
Podiceps B.V. |
Diagnostic of pre-symptomatic metabolic syndrome
|
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
|
FR2933702A1
(fr)
|
2008-07-08 |
2010-01-15 |
Sanofi Aventis |
Antagonistes specifiques du recepteur fgf-r4
|
|
WO2010006214A1
(en)
|
2008-07-09 |
2010-01-14 |
Ambrx, Inc. |
Fgf-21 neutralizing antibodies and their uses
|
|
CA2732449A1
(en)
|
2008-08-04 |
2010-02-11 |
Five Prime Therapeutics, Inc. |
Fgfr extracellular domain acidic region muteins
|
|
US9279013B2
(en)
|
2008-10-10 |
2016-03-08 |
Amgen Inc. |
FGF-21 mutants comprising polyethylene glycol and uses thereof
|
|
WO2010065439A1
(en)
|
2008-12-05 |
2010-06-10 |
Eli Lilly And Company |
Variants of fibroblast growth factor 21
|
|
US20120035105A1
(en)
|
2009-01-09 |
2012-02-09 |
Sdg, Inc. |
Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
|
|
WO2010083051A2
(en)
|
2009-01-15 |
2010-07-22 |
ProChon Biotech, Ltd. |
Cartilage particle tissue mixtures optionally combined with a cancellous construct
|
|
CN117050147A
(zh)
|
2009-02-03 |
2023-11-14 |
阿穆尼克斯制药公司 |
延伸重组多肽和包含该延伸重组多肽的组合物
|
|
UY38740A
(es)
|
2009-05-05 |
2020-12-31 |
Amgen Inc |
Mutantes de fgf21 y usos del mismo
|
|
MX2011011815A
(es)
|
2009-05-05 |
2012-01-27 |
Amgen Inc |
Mutantes fgf21 y usos de los mismos.
|
|
US8461111B2
(en)
|
2009-05-20 |
2013-06-11 |
Florida State University Research Foundation |
Fibroblast growth factor mutants having improved functional half-life and methods of their use
|
|
US20120076729A1
(en)
|
2009-06-04 |
2012-03-29 |
Novartis Ag |
Methods of treating cancers
|
|
WO2010142665A1
(en)
|
2009-06-11 |
2010-12-16 |
Novo Nordisk A/S |
Glp-1 and fgf21 combinations for treatment of diabetes type 2
|
|
AU2010262927A1
(en)
|
2009-06-17 |
2012-01-19 |
Amgen Inc. |
Chimeric FGF19 polypeptides and uses thereof
|
|
CN101993485B
(zh)
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
促胰岛素分泌肽类似物同源二聚体及其用途
|
|
JP6016636B2
(ja)
|
2009-10-15 |
2016-10-26 |
ジェネンテック， インコーポレイテッド |
改変したレセプター特異性を持つキメラ線維芽細胞増殖因子
|
|
US8889621B2
(en)
|
2009-10-30 |
2014-11-18 |
New York University |
Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
|
|
SG177025A1
(en)
*
|
2010-06-21 |
2012-01-30 |
Agency Science Tech & Res |
Hepatitis b virus specific antibody and uses thereof
|
|
AU2010326024A1
(en)
|
2009-12-02 |
2012-07-05 |
Amgen Inc. |
Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho
|
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
|
US20110312881A1
(en)
|
2009-12-21 |
2011-12-22 |
Amunix, Inc. |
Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
|
|
EP2460527A1
(en)
|
2010-01-21 |
2012-06-06 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
|
US20110195077A1
(en)
|
2010-01-29 |
2011-08-11 |
Novartis Ag |
Methods and compositions using fgf23 fusion ppolypeptides
|
|
CA2796055A1
(en)
|
2010-04-15 |
2011-10-20 |
Amgen Inc. |
Human fgf receptor and .beta.-klotho binding proteins
|
|
CA2796459C
(en)
|
2010-04-16 |
2016-05-24 |
Salk Institute For Biological Studies |
Methods for treating metabolic disorders using fgf-1
|
|
JP2013533227A
(ja)
|
2010-06-08 |
2013-08-22 |
ノヴォ ノルディスク アー／エス |
Ｆｇｆ２１類似体および誘導体
|
|
WO2012010553A1
(en)
|
2010-07-20 |
2012-01-26 |
Novo Nordisk A/S |
N-terminal modified fgf21 compounds
|
|
US20130216608A1
(en)
|
2010-09-09 |
2013-08-22 |
Trifoilium Aps |
Airway Administration of Angiogenesis Inhibitors
|
|
CA2814780C
(en)
|
2010-09-22 |
2017-05-16 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
|
CN102464712A
(zh)
|
2010-11-11 |
2012-05-23 |
重庆富进生物医药有限公司 |
缺失型人成纤维细胞生长因子21变异体及其偶联物
|
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
|
CN103402536A
(zh)
|
2010-12-22 |
2013-11-20 |
马克迪亚生物科技公司 |
用gip和glp-1受体活性的基于胰高血糖素的肽来治疗代谢异常和肥胖的方法
|
|
JP5850435B2
(ja)
|
2010-12-24 |
2016-02-03 |
国立研究開発法人産業技術総合研究所 |
ヒトｆｇｆ１９活性の正確で高感度な測定方法ならびにヒトｆｇｆ１９活性の制御剤
|
|
CN103533951B
(zh)
|
2011-04-08 |
2017-04-19 |
安姆根有限公司 |
使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法
|
|
WO2012140650A2
(en)
|
2011-04-12 |
2012-10-18 |
Hepacore Ltd. |
Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
|
|
JP2014513981A
(ja)
|
2011-05-10 |
2014-06-19 |
アムジエン・インコーポレーテツド |
ＦＧＦＲ１とβ−ＫＬＯＴＨＯの相互作用を特異的に調節する化合物の同定方法
|
|
AR090017A1
(es)
|
2011-05-16 |
2014-10-15 |
Genentech Inc |
Agonistas de fgfr1 y sus metodos de uso
|
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
|
KR20140039278A
(ko)
|
2011-06-08 |
2014-04-01 |
드노보 바이오파마 (항주) 리미티드 코포레이션 |
레티노이드 x 수용체 모듈레이터 활성 예측 방법 및 조성물
|
|
WO2012177481A2
(en)
|
2011-06-24 |
2012-12-27 |
University Of Miami |
Fibroblast growth factor receptor inhibition for the treatment of disease
|
|
SG10201806648TA
(en)
|
2011-07-01 |
2018-09-27 |
Ngm Biopharmaceuticals Inc |
Compositions, uses and methods for treatment of metabolic disorders and diseases
|
|
EP2548570A1
(en)
|
2011-07-19 |
2013-01-23 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
|
WO2013027191A1
(en)
|
2011-08-25 |
2013-02-28 |
Novartis Ag |
Methods and compositions using fgf23 fusion polypeptides
|
|
WO2013033452A2
(en)
|
2011-08-31 |
2013-03-07 |
Amgen Inc. |
Method of treating or ameliorating type 1 diabetes using fgf21
|
|
TW201315742A
(zh)
|
2011-09-26 |
2013-04-16 |
Novartis Ag |
治療代謝病症之雙功能蛋白質
|
|
US9006400B2
(en)
|
2011-09-26 |
2015-04-14 |
Novartis Ag |
Fibroblast growth factor-21-Fc fusion proteins
|
|
AR087973A1
(es)
|
2011-10-04 |
2014-04-30 |
Lilly Co Eli |
Variantes del factor 21 del crecimiento de fibroblastos
|
|
JP5936702B2
(ja)
|
2011-11-11 |
2016-06-22 |
ライナット ニューロサイエンス コーポレイション |
Ｔｒｏｐ−２に対して特異的な抗体およびこれらの使用
|
|
CA2862424A1
(en)
|
2012-01-18 |
2013-07-25 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
|
US9475856B2
(en)
|
2012-03-02 |
2016-10-25 |
New York University |
Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
|
|
JP2013194049A
(ja)
|
2012-03-23 |
2013-09-30 |
Kazuo Todokoro |
ヒト造血幹細胞を増幅させるための組成物及び方法
|
|
US8999380B2
(en)
|
2012-04-02 |
2015-04-07 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
|
WO2013156920A1
(en)
|
2012-04-16 |
2013-10-24 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Klotho variant polypeptides and uses thereof in therapy
|
|
SG11201407655TA
(en)
|
2012-05-15 |
2014-12-30 |
Lilly Co Eli |
Therapeutic uses of fibroblast growth factor 21 proteins
|
|
US9464126B2
(en)
|
2012-06-07 |
2016-10-11 |
New York University |
Chimeric fibroblast growth factor 21 proteins and methods of use
|
|
US9474785B2
(en)
|
2012-06-07 |
2016-10-25 |
New York University |
Chimeric fibroblast growth factor 19 proteins and methods of use
|
|
US9657075B2
(en)
|
2012-06-07 |
2017-05-23 |
New York University |
Chimeric fibroblast growth factor 23 proteins and methods of use
|
|
TWI513705B
(zh)
|
2012-06-11 |
2015-12-21 |
Lilly Co Eli |
纖維母細胞生長因子２１蛋白質
|
|
EA201492064A1
(ru)
|
2012-06-11 |
2015-02-27 |
Эли Лилли Энд Компани |
Варианты фактора роста фибробластов 21
|
|
BR112015000653A2
(pt)
|
2012-07-11 |
2019-11-05 |
Blueprint Medicines Corp |
compostos inibidores do receptor de fator de crescimento de fibroblasto, sua composição farmacêutica e seus usos
|
|
TW201420606A
(zh)
|
2012-08-22 |
2014-06-01 |
Lilly Co Eli |
同源二聚體蛋白
|
|
CA2880929A1
(en)
|
2012-09-07 |
2014-03-13 |
Sanofi |
Fusion proteins for treating a metabolic syndrome
|
|
US9963494B2
(en)
|
2012-11-28 |
2018-05-08 |
Ngm Biopharmaceuticals, Inc. |
Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject
|
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
RU2675514C2
(ru)
|
2012-12-27 |
2018-12-19 |
ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. |
Способы модуляции гомеостаза желчных кислот и лечение расстройств и заболеваний, ассоциированных с желчными кислотами
|
|
WO2014130659A1
(en)
|
2013-02-22 |
2014-08-28 |
New York University |
Chimeric fibroblast growth factor 23 proteins and methods of use
|
|
WO2014152090A1
(en)
|
2013-03-14 |
2014-09-25 |
Georgetown University |
Compositions and treatments of metabolic disorders using fgf binding protein 3 and fgf 19
|
|
WO2014149699A1
(en)
|
2013-03-15 |
2014-09-25 |
Eli Lilly And Company |
Bifunctional protein
|
|
AU2014340241B2
(en)
|
2013-10-21 |
2018-11-01 |
Salk Institute For Biological Studies |
Mutated fibroblast growth factor (FGF) 1 and methods of use
|
|
WO2015065897A1
(en)
|
2013-10-28 |
2015-05-07 |
Ngm Biopharmaceuticals, Inc. |
Cancer models and associated methods
|
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
|
CN106662577B
(zh)
|
2014-01-24 |
2020-07-21 |
恩格姆生物制药公司 |
结合蛋白及其使用方法
|
|
US10398758B2
(en)
|
2014-05-28 |
2019-09-03 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
|
|
WO2015195509A2
(en)
|
2014-06-16 |
2015-12-23 |
Ngm Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
KR102569907B1
(ko)
|
2014-10-23 |
2023-08-24 |
엔지엠 바이오파마슈티컬스, 아이엔씨. |
펩티드 변이체를 포함하는 약제학적 조성물 및 그의 사용 방법
|
|
WO2016073855A1
(en)
|
2014-11-07 |
2016-05-12 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
|
US10800843B2
(en)
|
2015-07-29 |
2020-10-13 |
Ngm Biopharmaceuticals, Inc. |
Beta klotho-binding proteins
|
|
WO2017083276A1
(en)
|
2015-11-09 |
2017-05-18 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders
|
|
AU2017315459B2
(en)
|
2016-08-26 |
2023-06-29 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
|
|
US20190307847A1
(en)
|
2016-08-29 |
2019-10-10 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders
|